BioSpace News Archive

The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.

Generate Biomedicines, a machine-learning protein-therapy company, raked in $370 million in a Series B financing round that will be used to advance the company’s developmental programs.

Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.

Merck’s Keytruda (pembrolizumab) keeps expanding the indications for which it’s approved. The company announced today that the FDA had approved the anti-PD-1 therapy for adjuvant treatment of renal cell carcinoma.

Abeona Therapeutics Inc. today announced its sponsorship of the second annual Venture Into Cures , a virtual event supporting EB Research Partnership’s mission to find a cure for epidermolysis bullosa (EB).

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company has received positive scientific advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency related to the pediatric label extension for NexoBrid.

Artizan Biosciences, Inc. and Biohaven Therapeutics Ltd. today announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD).

Verrica Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug Application (“IND”) for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

BridgeBio Pharma, Inc. today announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to $750.0 million in financing.

Heron Therapeutics, Inc. today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults.